Health Care Equipment & Services

NewGenIVF’s CEO buys 73,647 employee options, signaling strong leadership confidence and a bullish outlook for the biotech’s future growth.

CEO Michael Farrell’s disciplined 10b5‑1 trades reveal ResMed’s growth confidence: buying below $150, selling near $220, amid strategic sales and acquisitions that bolster future cash flow and share‑buybacks.

Concord Medical CFO keeps 477,000 shares steady, signaling confidence amid a volatile market and hinting at future growth opportunities.

GLAUKOS CFO’s mixed buy‑sell trade shows bullish confidence in the glaucoma therapy stock, hinting at future upside despite its negative P/E.

Explore the implications of Navratil Tomas’s recent Glaukos insider sale—understand the impact on liquidity, investor sentiment, and the company’s growth outlook.

CEO Sean Duffy’s 2,800‑share OMADA Health buy signals insider confidence and hints at future bullish moves, even amid social‑media buzz.

Insider selling trend at Simulations Plus: Chief Revenue Officer DiBella’s recent 1,000‑share sale hints at a cautious portfolio shift amid rising drug‑simulation prospects.

Insider sales at SOPHiA GENETICS show disciplined liquidity planning, not a confidence dip—executive Jurgi’s July 7 trade confirms strong, rising fundamentals.

Inside BTOA’s July 1 sales: Nancy JoAnn Johnson’s disciplined 801‑share sale at $124.91 shows personal liquidity moves, not a confidence shift, amid a high‑growth healthcare stock.

Insider sale by Walter Woltosz reveals disciplined 10b‑5‑1 trading but hints at rising valuation for Simulations Plus, a fast‑growing health‑tech stock.